Summary: Obesity drug developer BioAge seeking up to $587 million valuation in US IPO, healthcare firms performing well in subdued US IPO market in 2024, BioAge's azelaprag is a GLP-1 agonist like Zepbound and Wegovy
Full articleSummary: Thermo Fisher Scientific's PPD clinical research business is expanding its global laboratory services with a new bioanalytical lab in Gothenburg, Sweden, adjacent to AstraZeneca's research site. The new lab will offer advanced technologies and methodologies to support pharmaceutical and biotech customers across all phases of drug development.
Full articleSummary: The press release discusses the Bioacoustics Sensing System market segmentation, business strategies, and key players such as AT&T, IBM, and Samsung Electronics. It also emphasizes the importance of understanding competitor financials and potential partnerships for business growth.
Full article